Switch-On
Research type
Research Study
Full title
A Prospective, Non-Interventional Study on the Long-term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIGON®) in Patients with Parkinson’s Disease Previously Treated with Subcutaneous Foslevodopa in Routine Care
IRAS ID
360935
Contact name
Alan Whone
Contact email
Sponsor organisation
Britannia Pharmaceuticals Ltd
Duration of Study in the UK
2 years, 10 months, 1 days
Research summary
The SWITCH-ON study is a prospective, international, non-interventional study (observes people without changing their treatment or behaviour).
Data will be collected prospectively (what is anticipated to happen). Patients will be followed for 12 months after starting LECIGON® or until withdrawal, general practitioner discretion, loss to follow-up, death, or early study termination, whichever occurs first.
No interventions beyond routine clinical practice will be administered during the study. All treatments and procedures follow standard of care guidelines. Patients will be discontinued from the study if they discontinue treatment with LECIGON®.
The purpose of the SWITCH-ON study is to collect real-world data on the long-term effectiveness of LECIGON® in routine clinical practice in adult patients with advanced Parkinson's Disease (PD) in patients who have discontinued treatment with foslevodopa-foscarbidopa (a combination medication used to treat advanced PD, especially in patients experiencing motor fluctuations that aren't well-controlled by oral medications).
Approximately 215 patients will be enrolled from approximately 30 specialised PD centres within 5 European countries (Germany, UK, Spain, Netherlands, and Romania).
Patients receive LECIGON® as part of their routine care. The decision to prescribe LECIGON® is made independently of study inclusion and follows existing clinical practice guidelines. Patients will be discontinued from the study if they discontinue treatment with LECIGON®.REC name
London - London Bridge Research Ethics Committee
REC reference
26/PR/0115
Date of REC Opinion
9 Mar 2026
REC opinion
Further Information Favourable Opinion